{"title":"Metabolic Health","description":"","products":[{"product_id":"ap3-r","title":"AP3-R","description":"\u003cp\u003eA triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors. Available in 15mg, 20mg, and 30mg lyophilized vials, third-party tested at 98%+ purity.\u003c\/p\u003e\n\n\u003ch3\u003eWhat Is AP3-R?\u003c\/h3\u003e\n\u003cp\u003eAP3-R is research-grade retatrutide — a novel triple-agonist peptide that activates three distinct receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This tri-receptor mechanism distinguishes it from single and dual-agonist compounds currently under investigation. In Phase 2 clinical trials published in \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e, retatrutide demonstrated significant effects on metabolic parameters including body weight, glucose regulation, and lipid profiles.\u003c\/p\u003e\n\n\u003ch3\u003eHistory\u003c\/h3\u003e\n\u003cp\u003eRetatrutide was developed by Eli Lilly and Company and first entered clinical investigation in 2021. The compound emerged from research into multi-receptor agonism as an approach to metabolic disease, building on the success of dual-agonist compounds like tirzepatide. The Phase 2 trial results, published in 2023, generated significant interest in the research community due to the magnitude of metabolic effects observed with tri-receptor activation. Phase 3 trials are ongoing as of 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eFor research purposes only. Not for human consumption.\u003c\/em\u003e\u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"15MG","offer_id":44740617568301,"sku":null,"price":210.0,"currency_code":"COP","in_stock":true},{"title":"20MG","offer_id":44740617601069,"sku":null,"price":220.0,"currency_code":"COP","in_stock":true},{"title":"30MG","offer_id":44746867146797,"sku":null,"price":235.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/Reta_36887945-64cc-42de-b8d3-db684df20297.png?v=1777073013"},{"product_id":"ap2-t","title":"AP2-T","description":"\u003cp\u003eA dual GIP\/GLP-1 receptor agonist widely studied for metabolic research. Lyophilized (freeze-dried) form, verified 98%+ purity. Available in 15mg and 30mg vials.\u003c\/p\u003e\n\n\u003ch3\u003eWhat Is AP2-T?\u003c\/h3\u003e\n\u003cp\u003eAP2-T is research-grade tirzepatide — a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Originally developed as an investigational compound for metabolic research, tirzepatide has become one of the most widely studied peptides in clinical settings. Published research in \u003cem\u003eThe New England Journal of Medicine\u003c\/em\u003e and \u003cem\u003eThe Lancet\u003c\/em\u003e has documented its effects on glycemic control, body composition, and metabolic biomarkers.\u003c\/p\u003e\n\n\u003ch3\u003eHistory\u003c\/h3\u003e\n\u003cp\u003eTirzepatide was developed by Eli Lilly and Company, with the first clinical trial results published in 2018. The compound received regulatory approval in 2022 under the brand name Mounjaro for a specific clinical application, followed by additional approval as Zepbound in 2023. The SURPASS and SURMOUNT clinical trial programs generated extensive published data on tirzepatide's dual-incretin mechanism. It remains one of the most actively investigated compounds in metabolic research.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eFor research purposes only. Not for human consumption.\u003c\/em\u003e\u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"20MG","offer_id":44807950204973,"sku":null,"price":129.0,"currency_code":"COP","in_stock":true},{"title":"30MG","offer_id":44807950237741,"sku":null,"price":199.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/Tirz20mg.webp?v=1777072944"},{"product_id":"aod-9604","title":"AOD-9604","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA modified fragment (amino acids 177–191) of human growth hormone, studied for its effects on lipid metabolism without impacting blood sugar or growth.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is AOD-9604?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAOD-9604 is a synthetic peptide analog of the C-terminal fragment of human growth hormone, corresponding to amino acids 177–191 with a tyrosine modification. Unlike full-length growth hormone, AOD-9604 has been studied for its ability to stimulate lipolysis and inhibit lipogenesis without affecting blood glucose levels or promoting cell proliferation. Research has investigated its mechanism of action through beta-3 adrenergic receptor pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAOD-9604 was originally developed by Metabolic Pharmaceuticals in Australia during the late 1990s. The peptide emerged from research by Professor Frank Ng at Monash University, who identified that the fat-reducing activity of growth hormone resided in its C-terminal fragment. The compound advanced through Phase 2 clinical trials before development was paused. More recently, AOD-9604 has received attention in the research community for potential applications beyond lipid metabolism, including cartilage repair.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"5MG","offer_id":44807966031917,"sku":null,"price":49.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/AOD-96045mg_0ce59e76-d299-48f6-acda-4c3395414b59.png?v=1775603636"},{"product_id":"mots-c","title":"MOTS-C","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA 16-amino-acid peptide encoded by mitochondrial DNA, studied for metabolic regulation, exercise mimetic properties, and longevity research.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is MOTS-C?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMOTS-C (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondria-derived peptide encoded by the mitochondrial genome. Discovered by Dr. Changhan David Lee’s research group at USC, MOTS-C represents a relatively new class of signaling molecules. Published research has shown MOTS-C activates AMPK, a master metabolic regulator, and has been described as an “exercise mimetic.”\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eMOTS-C was discovered in 2015 by Dr. Changhan David Lee and colleagues at the University of Southern California Leonard Davis School of Gerontology. The peptide was identified through computational analysis of the mitochondrial genome, revealing previously unrecognized open reading frames encoding bioactive peptides. The discovery of MOTS-C and its sister peptide humanin opened an entirely new field of research into mitochondria-derived peptides (MDPs) as intercellular signaling molecules. Subsequent research demonstrated MOTS-C’s role in metabolic regulation, exercise physiology, and aging.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"10MG","offer_id":44808017575981,"sku":null,"price":69.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/MOTS-C.png?v=1775605969"}],"url":"https:\/\/protocolaminos.com\/collections\/metabolic-health.oembed","provider":"Protocol Aminos","version":"1.0","type":"link"}